TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Proof of Concept: Socket Seal

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~• Planned extraction in the upper front or premolar region~Exclusion Criteria:~* General risk situation (antiresorptive therapy, antiangiogenic therapy, history of local radiation therapy, heavy coagulation disorder, relevant allergies, dysregulated Diabetes mellitus, malignant diseases)~* Acute gingivitis~* Deep pockets (\>5.5mm)~* Apical periodontitis on neighboring teeth~* Heavy smoker (\>10/d)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- 1. Mucograft® Seal + Bio-Oss® (Type: ACTIVE_COMPARATOR): None
- 2. FGG + Bio-Oss® (Type: ACTIVE_COMPARATOR): None
- 3. FGG + Gelatine sponge (Spongostan®) (Type: ACTIVE_COMPARATOR): None
- 4. Spongostan®+ Mucograft® Seal (Type: ACTIVE_COMPARATOR): None
- 5. Spongostan® (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Efficacy of ONS to Reduce Postoperative Complications Associated With Pancreatic Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 40-89 at the time of study enrollment.~2. Undergoing pancreatectomy for either chronic pancreatitis or pancreatic cancer.~3. Ability and willingness to complete study related documents and activities.~Exclusion Criteria:~1. Severe malnutrition that in the judgment of the patient's supervising physician or an investigator would not permit surgical intervention without preoperative nutritional support (enteral or parenteral).~2. Subject is receiving (or planned to receive) enteral tube feeding or parenteral nutrition at the time of screening or before surgery.~3. Surgery is planned within 7 days of enrollment (i.e., inadequate time to offer the study intervention).~4. Known allergy to soy or milk, which are included in the oral supplement.~5. The inability to refrain from using a non-study oral nutritional supplement or fish oil supplementation (unless prescribed for treatment of hyperlipidemia).~6. Pregnancy, incarceration, or inability to provide written informed consent.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: OTHER): Subjects randomized to this arm will receive: An Oral Nutritional Supplementation (Ensure Surgical), home-based resistance training, and dietary counseling
- Nutrition Counseling alone (Type: OTHER): Subjects randomized to this arm will receive: Dietary counseling along with standard of care procedures.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Topiramate as a Treatment for Levodopa-Induced Dyskinesia in Parkinson's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* UK PD Society Brain Bank criteria for the diagnosis of idiopathic PD.~* Patients with stable levodopa-induced dyskinesias present greater than 25% of the day (Unified Parkinson's Disease Rating Scale (UPDRS), item 32, rating \> 2) and be moderately to completely disabling (UPDRS item 33, rating \> 2).~* All anti-parkinsonian medications must be stable for at least one month prior to study enrollment.~Exclusion Criteria:~* Include prior surgery for PD~* Hoehn and Yahr score of 5 when off~* History of nephrolithiasis~* Renal impairment~* Liver disease~* Pregnancy~* Premenopausal females and males not using adequate contraception~* Cognitive impairment (Mini Mental State Exam score less than 24)~* History of glaucoma or seizures~* Use of other antiepileptic drugs~* Amantadine~* Carbonic anhydrase inhibitors~* Digoxin~* Metformin~* Or illicit drugs

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Medical Optimization of Management of Type 2 Diabetes Complicating Pregnancy (MOMPOD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Maternal age 18-45 years~* Singleton pregnancy with no known fetal anomalies~* Gestational age between 10weeks 0 days and 22 weeks 6 days by menstrual dating confirmed by ultrasound, or ultrasound alone~* Clinical diagnosis of preexisting T2DM requiring medical treatment (oral agent or insulin)~* Clinical diagnosis of diabetes diagnosed between 10 weeks and \< 20 weeks 6 days gestation~* Willing to start insulin therapy and discontinue oral hypoglycemic pills other than study pills~* Able to swallow pills~Exclusion Criteria:~* Clinical diagnosis of pre-existing renal disease, defined as creatinine \> 1.5 mg/dL~* Clinical history of lactic acidosis~* Known allergy to metformin~* Participation in another study that could affect primary outcome~* Delivery planned at non-MOMPOD study locations~* Unwillingness to use insulin treatment or follow prenatal care doctor's instructions for insulin and blood glucose monitoring

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: ACTIVE_COMPARATOR): Metformin 1000 mg twice a day
- Placebo (Type: SHAM_COMPARATOR): Placebo, identical to Metformin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Elastography for Evaluating Cervical Maturity in Preparation for Labor Induction at 37 to 42 Weeks of Gestation

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* The patient must have given her informed and signed consent~* The patient must be insured or beneficiary of a health insurance plan~* Pregnant woman with a medical indication for pre-term labor induction: 37 to 42 weeks of gestation.~Exclusion Criteria:~* The patient is in an exclusion period determined by a previous study~* The patient is under judicial protection, under tutorship or curatorship~* The patient refuses to sign the consent~* It is impossible to correctly inform the patient~* History of cervical surgery~* Malformation of the cervix

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- The study population (Type: None): The study population is composed of pregnant women with a medical indication for the induction of pre-term (37-42 weeks of gestation) labor and who are consulting in the participating center.~Intervention: Cervical ultrasound with elastography

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Miltefosine for Brazilian Visceral Leishmaniasis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed (untreated) visceral leishmaniasis with symptomatic disease and visualization of amastigotes in tissue samples or a positive culture.~  * Age: Group 1: 2 to 12 years; Group 2: 13 to 60 years~ * Sex: male and female patients eligible (no effort to be made to balance the study for gender)~Exclusion Criteria:~Exclusion criteria~Safety concerns:~* Thrombocyte count \<30 x 109/l;~* Leukocyte count \<1 x 109/l;~* Hemoglobin \<5 g/100 ml;~* ASAT, ALAT, AP \>3 times upper limit of normal range;~* Serum creatinine or BUN \>1.5 times upper limit of normal range;~* Evidence of serious underlying disease (cardiac, renal, hepatic or pulmonary);~* Immunodeficiency or antibody to HIV;~* Severe protein and/or caloric malnutrition (Kwashiorkor, Marasmus);~* Any non-compensated or uncontrolled condition;~* Lactation, pregnancy (to be determined by adequate test) or inadequate contraception in females of childbearing potential for treatment period plus 2 months.~Lack of suitability for the trial:~* Negative bone marrow aspirate (smear);~* Any history of prior anti-leishmania therapy;~* Any condition which compromises ability to comply with the study procedures;~* Concomitant serious infection other than visceral leishmaniasis (this would include evidence of other conditions associated with splenomegaly such as schistosomiasis or malaria).~Administrative reasons:~* Lack of ability or willingness to give informed consent (patient and/or parent / legal representative);~* Anticipated non-availability for study visits/procedures.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Early Goal-directed Fluid Therapy in Septic Patients Undergoing Emergency Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults \> 18 years~* Severe sepsis\* as defined by the ACCCP/SCCM consensus conference~* Need for emergent interventional procedure under general anesthesia with an expected duration \> 120 min (in and out patients).~Exclusion Criteria:~* Patients responding to early fluid resuscitation (20ml/kg) who don't require a CVC~* Neurotrauma (Glasgow Coma Score \< 12) and/ or medullar trauma~* Known pregnancy or diagnosed by US or Ct-scan (\> 14 weeks)~* Sustained cardiac arrhythmia (see Logbook P8)~* Known or diagnosed severe cardiac valvular dysfunction (stenosis, insufficiency) (see Logbook P8)~* Known or diagnosed intracardiac shunt: interventricular or atrial defect (see Logbook P8)~* Burn injury \> 10%~* Needed emergency thoracotomy or ABC resuscitation protocol~* Pre-existing severe liver dysfunction(Child-Pugh class C)~* Do-not-resuscitate order, died within 48h of admission

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CONTROL (Type: ACTIVE_COMPARATOR): In the CONTROL group, the administration of fluid (250-500ml crystalloids or colloids) and cardiovascular supportive drugs will be guided to maintain standard pressure-related parameters within a normal range: MAP \> 65mmHg, HR \< 90/min, CVP \>8-12\< cm H20, urinary output \> 0.5 ml/kg/h. In line with the conventional approach, other physiological parameters will also be targeted: T° \> 35.5°C, Sp02 \> 95%, lactate \< 2.5 mmol/L, normalisation of the BE. The maximal infused volume of hydroxyethyl starch (Voluven®) will be 33 ml/kg.~At the discretion of the attending anaesthesiologist with the FMH level, a pulmonary artery catheter, a transoesophageal Doppler flow probe or the PiCCO monitor will be inserted to complement the standard hemodynamic monitoring if deemed necessary.
- OPTIMIZED (Type: ACTIVE_COMPARATOR): In the OPTIMIZED group, the central venous catheter and the 4-French artery catheter (femoral or humeral access site) will be connected to a dedicated haemodynamic monitor (Pulsiocath, PV2024L; Pulsion Medical Systems AG, Munich, Germany).~The administration of fluid (250-500ml crystalloids or colloids) and cardiovascular supportive drugs will be guided by an algorithm taking into account standard parameters (HR, MAP, lactate, Hb), as well as static and dynamic volumetric parameters (SVI, CI, GEDVI, EVLWI, SVV, PPV, PVI).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Natural History Study of Infants and Children With Developmental and Epileptic Encephalopathies

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Aged between 6 months and 60 months.~* Confirmed SCN1A mutation.~* Normal development prior to onset of first seizure as defined by the Centers for Disease -Control and Prevention (CDC 2019).~* Onset of seizures between age 3 and 15 months, inclusive.~Exclusion Criteria:~* Copy number variant of SCN1A, including SCN1A microdeletion, if affecting other genes.~* SCN1A mutation present on both alleles.~* Known pathogenic or clinically suspected mutation in a seizure-associated gene besides SCN1A.~* Confirmed mutation in a gene besides SCN1A that is known to increase the severity of the seizure phenotype.~* Known gain-of-function genetic mutation, as defined by functional studies, including p.Thr226Met.~* History of notable developmental deficit that was evident prior to seizure onset.~* Known central nervous system structural abnormality as found on magnetic resonance imaging or computed tomography scan of brain.~* Currently taking or has taken for 6 or more consecutive weeks anti-seizure medications (ASMs) at a therapeutic dose that are contraindicated in SCN1A-positive Dravet Syndrome, including sodium channel blockers.~* Known concomitant genetic mutation or clinical comorbidity that potentially confounds typical Dravet phenotype.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 60 Months
- Healthy Volunteers: f

Study Arms:
- SCN1A-positive Dravet Syndrome (Type: None): Participants aged between 6 and 60 months of age who have SCN1A-positive Dravet Syndrome. Clinical, neurocognitive, laboratory, the burden of disease, and health care resource utilization will be assessed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patients must be treated by nephrectomy and patients must meet all of the following inclusion criteria to be eligible for enrollment into the trial:~1. Patients must have no evidence of macroscopic residual disease or metastatic disease.~2. Male or female, age \>=18 years (age \>=20 years in Japan, Korea and Taiwan).~3. Patients must be diagnosed with one of the following based on American Joint Committee on Cancer (AJCC) TNM staging version 2010, Eastern Collaborative Oncology Group (ECOG) performance status (PS):~   * pT2, pN0 or pNx, M0 and ECOG PS 0-1~  * pT3, pN0 or pNx, M0 and ECOG PS 0-1~  * pT4, pN0 or pNx, M0 and ECOG PS 0-1~  * Any pT, pN1, M0 and ECOG PS 0-1~4. Patients must have histologically confirmed preponderant, defined as \>50%, clear cell RCC.~5. Patients must not have received any previous systemic (includes chemotherapeutic, hormonal, or immunotherapeutic) treatment for RCC.~6. Patients must not have received any previous anti angiogenic treatment.~7. Patients must have adequate organ function.~Exclusion Criteria~1. Histologically undifferentiated carcinomas, sarcomas, collecting duct carcinoma, lymphoma, or patients with any metastatic renal sites.~2. National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Grade 3 hemorrhage \<4 weeks of date of randomization.~3. Diagnosis of any non-RCC malignancy within the 5 years from date of randomization, except basal cell carcinoma, squamous cell skin cancer, or in situ carcinoma of the cervix uteri that has been adequately treated with no evidence of recurrent disease for 12 months.~4. Any of the following within the 12 months prior to study drug administration: myocardial infarction, uncontrolled angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack and 6 months for deep vein thrombosis or pulmonary embolism.~5. Gastrointestinal abnormalities

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Axitinib (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Salvage Chemotherapy (R-ESHAP) to Treat Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of aggressive non-Hodgkin's lymphoma~* Refractory to the first line chemotherapy or relapsed~* Expression of CD20 on lymphoma cells~* Measurable lesions on imaging studies~Exclusion Criteria:~* Blood cell counts not reaching to 3,000/microliter for white blood cells, 7 g/dl for hemoglobin, and 50,000/microliter for platelets without transfusion at the time of registration~* Circulating lymphoma cells equal to or more than 25,000/microliter~* Hepatic dysfunction~* Renal insufficiency~* Cardiac dysfunction or arrhythmia~* Sever infection (bacterial, viral)~* CNS involvement~* Other malignancies~* Pregnancy or breast feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 69 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: HCT Versus CT in Elderly AML

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 60years and ≤ 75 years~* primary or secondary AML as defined by WHO or refractory anemia with excess of blasts (RAEB)~* First complete remission following one or two cycles of induction chemotherapy~* Chemotherapy was administered according to current participating cooperative group protocols~* Karnofsky score ≥ 70~* Written informed consent~Exclusion Criteria:~* AML FAB M3~* HIV positivity~* Participation in another clinical trial without prior consent of the coordinating investigator, patients may exceptionally take part in a further study only if~  * The second study exclusively concerns induction therapy~ * Consolidation cycle one and two are given according to the accredited study group policy~ * No investigational drugs are used post registration for the HCT vs CT in eldery AML study.~ * Documentation for the HCT vs CT in eldery AML study is not compromised. Second hand data from foreign study is not accepted

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Transplant Arm (Type: EXPERIMENTAL): Hematopoietic cell transplantation after Reduced Intensity Conditioning
- Conventional Chemotherapy (Type: ACTIVE_COMPARATOR): The non-transplant treatment approach for consolidation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: 18F-FTC-146 PET/CT in Newly-Diagnosed Osteosarcoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with biopsy proven osteosarcoma requiring local surgical intervention.~* ECOG ≤ 2~* Ability to understand and the willingness to sign a written informed consent document.~Exclusion Criteria:~* Chemotherapy in the past 2 months.~* Prior history of allergic reaction to 18F FTC 146.~* Pregnant or nursing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 18-F-FTC 146 PET/CT (Type: EXPERIMENTAL): For PET scans, subjects will receive intravenous injection of 10 mCi 18-F -FTC 146 administered twice with 18-F-FTC 146, once at baseline (pre chemotherapy) and once at final study visit (post chemotherapy).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Reducing Perioperative S. Aureus Transmission

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years of age~* Undergoing surgery (orthopedic total joint, orthopedic spine, Gynecological/Oncology, thoracic, general, hernia, colorectal, open vascular, plastic surgery and open urological)~* Ability to sign informed consent~* Require general or regional anesthesia~Exclusion Criteria:~* Less than 18 years of age~* Inability to sign informed consent~* Procedures not included above~* Not requiring general or regional anesthesia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Standard of Care (Type: NO_INTERVENTION): Patient will receive by mail a kit containing swab for the nares, armpit and groin.
- Swab kit plus povidone-iodine soap (Type: ACTIVE_COMPARATOR): Patient will receive by mail a kit containing swab for the nares, armpit and groin. In addition the patient will receive decolonization treatment including povidone-iodine soap for presurgical cleansing two days prior to surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility